Holen Sie sich die Stockscreener-App
9.61
4.80%
0.44
Handel nachbörslich:
9.63
0.02
+0.21%
Schlusskurs vom Vortag:
$9.17
Offen:
$9.16
24-Stunden-Volumen:
930.62K
Relative Volume:
0.75
Marktkapitalisierung:
$582.27M
Einnahmen:
$217.11M
Nettoeinkommen (Verlust:
$-651.19M
KGV:
-0.7398
EPS:
-12.99
Netto-Cashflow:
$-387.26M
1W Leistung:
+15.64%
1M Leistung:
+3.89%
6M Leistung:
-15.33%
1J Leistung:
-14.20%
1-Tages-Spanne:
$9.08
$9.75
1-Wochen-Bereich:
$8.33
$9.75
52-Wochen-Spanne:
$5.00
$17.58
Ginkgo Bioworks Holdings Inc Stock (DNA) Company Profile
Firmenname
Ginkgo Bioworks Holdings Inc
Sektor
Branche
Telefon
(877) 442-5362
Adresse
27 DRYDOCK AVENUE, BOSTON
Vergleichen Sie DNA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DNA
Ginkgo Bioworks Holdings Inc
|
9.61 | 555.61M | 217.11M | -651.19M | -387.26M | -12.99 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.15 | 118.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
812.27 | 81.61B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
422.50 | 53.69B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
822.94 | 49.49B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
176.00 | 37.34B | 447.02M | -1.18B | -906.14M | -6.1812 |
Ginkgo Bioworks Holdings Inc Stock (DNA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-05-15 | Herabstufung | BTIG Research | Neutral → Sell |
| 2024-05-10 | Herabstufung | William Blair | Mkt Perform → Underperform |
| 2023-11-14 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2023-11-09 | Herabstufung | BTIG Research | Buy → Neutral |
| 2023-06-02 | Herabstufung | Goldman | Neutral → Sell |
| 2023-05-11 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2022-11-29 | Eingeleitet | Berenberg | Buy |
| 2022-10-04 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2022-05-18 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2022-03-02 | Fortgesetzt | Cowen | Outperform |
| 2022-02-23 | Eingeleitet | Goldman | Neutral |
| 2022-02-01 | Eingeleitet | BofA Securities | Neutral |
| 2022-01-28 | Eingeleitet | BofA Securities | Buy |
| 2022-01-07 | Eingeleitet | BTIG Research | Buy |
| 2021-11-29 | Eingeleitet | Jefferies | Buy |
| 2021-10-13 | Eingeleitet | Raymond James | Outperform |
| 2021-10-12 | Eingeleitet | William Blair | Outperform |
| 2021-09-20 | Eingeleitet | HSBC Securities | Buy |
Alle ansehen
Ginkgo Bioworks Holdings Inc Aktie (DNA) Neueste Nachrichten
Why hedge funds are buying Ginkgo Bioworks Holdings Inc. stock2026 world cup usa national team qualification star players transition play odds analysis preview - ulpravda.ru
Ginkgo Bioworks (DNA) Upgraded to Strong Buy: Here's What You Should Know - MSN
Ginkgo Bioworks announces COO transition and operational leadership changes By Investing.com - Investing.com Australia
Ginkgo Bioworks announces COO transition and operational leadership changes - Investing.com
Is Ginkgo Bioworks Holdings Inc a good long term investmentInsider Trading Compliance & Affordable Trading Techniques - earlytimes.in
Penny Stocks That Will Make You Richcareer Html Definition Characteristics & How To Invest - shababeek.org
Ginkgo Bioworks Holdings, Inc. (DNA) rises as market takes a dip: Key facts - MSN
Ginkgo Bioworks Holdings, Inc. (DNA) Rises As Market Takes a Dip: Key Facts - Yahoo Finance
Ginkgo Bioworks Holdings Insider Sellers Miss The Bus As Stock Jumps 10.0% - simplywall.st
Liquidity Mapping Around (DNA) Price Events - Stock Traders Daily
Ginkgo Bioworks announces operating leadership transition effective January 2026 - Investing.com India
Ginkgo Bioworks realigns leadership, shifts COO responsibilities - MSN
Ginkgo Bioworks announces operating leadership transition effective January 2026 By Investing.com - Investing.com Australia
Ginkgo Bioworks Announces COO Transition - TradingView — Track All Markets
Ginkgo Bioworks shifts operating duties in leadership restructure - StreetInsider
Ginkgo Bioworks (NYSE: DNA) realigns leadership as Shetty refocuses on lab - Stock Titan
Ginkgo Bioworks Partners with Carnegie-Mellon University to Develop Innovative New Cancer Screening Approach - Sahm
Ginkgo Bioworks (DNA) Shares Rise On New Cancer Screening Approach Plans - Sahm
Ginkgo Bioworks, Carnegie Mellon Partner on At-Home Cancer Detection Technology - marketscreener.com
Ginkgo Bioworks partners with CMU on innovative cancer detection By Investing.com - Investing.com Canada
Ginkgo Bioworks (NYSE:DNA) Trading Up 10%Time to Buy? - MarketBeat
How rising interest rates impact Ginkgo Bioworks Holdings Inc. stock2025 Historical Comparison & Weekly Chart Analysis and Guides - bolumsonucanavari.com
Will Ginkgo Bioworks Holdings Inc. stock recover faster than marketJuly 2025 Price Swings & Low Drawdown Trading Strategies - Улправда
Is Ginkgo Bioworks Holdings Inc. stock resilient to inflationEarnings Miss & Consistent Income Trade Ideas - DonanımHaber
Is Ginkgo Bioworks Holdings Inc. stock a contrarian buy2025 Price Momentum & Weekly Top Performers Watchlists - Улправда
Can Ginkgo Bioworks Holdings Inc. stock rebound after recent weaknessJuly 2025 Rallies & Daily Profit Focused Stock Screening - DonanımHaber
Will Ginkgo Bioworks Holdings Inc. stock maintain momentum in 20252025 Volatility Report & Safe Capital Allocation Plans - Улправда
Ginkgo Bioworks, Agricen Collaborate on Soil Amendment Fermentation - marketscreener.com
Ginkgo Bioworks and Agricen complete fermentation process optimization By Investing.com - Investing.com Canada
Ginkgo Bioworks and Agricen Enter Collaboration to Optimize Manufacturing Processes for a Key Agricultural Soil Amendment - Finviz
New partnership speeds up production of helpful soil bacteria for crops - Stock Titan
CFO Coen Acquires 750 Of Ginkgo Bioworks Holdings Inc [DNA] - TradingView — Track All Markets
Ginkgo Bioworks Holdings, Inc. (DNA) insider details RSU vesting and tax sale - Stock Titan
DNA (NYSE: DNA) holder plans sale of 736 Class A shares on NYSE per notice - Stock Titan
Price-Driven Insight from (DNA) for Rule-Based Strategy - Stock Traders Daily
What analysts say about Ginkgo Bioworks Holdings Inc stockDividend Stability Analysis & Rapid Portfolio Gain - earlytimes.in
Ginkgo Bioworks awarded four-year, up to $47M contract from EMSL - MSN
ProteoNic 2G UNic® Technology Licensed by Ginkgo Bioworks for BARDA-Supported Consortium Advancing Monoclonal Antibody Manufacturing for Anti-Filovirus Therapies - Investing News Network
Jump Financial LLC Acquires New Stake in Ginkgo Bioworks Holdings, Inc. $DNA - MarketBeat
Treas Che Files To Sell 2,200 Of Ginkgo Bioworks Holdings Inc [DNA] - TradingView — Track All Markets
Ginkgo Bioworks (NYSE: DNA) insider files to sell 2,200 shares - Stock Titan
Recent Uptick Might Appease Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Institutional Owners After Losing 13% Over the Past Year - 富途牛牛
Ginkgo Bioworks partners on Deep Origin-led team to develop new tools for predicting drug safety - Investing News Network
Ginkgo Bioworks Partners With Deep Origin-Led Team on ARPA-H to Develop Drug Safety Platform - marketscreener.com
Ginkgo Bioworks Partners on Deep Origin-Led Team to Develop New Tools for Pred Predictive Drug Safety - marketscreener.com
Ginkgo Bioworks partners with Deep Origin on ARPA-H drug safety project - Investing.com UK
Ginkgo Bioworks (NYSE:DNA) Shares Gap UpWhat's Next? - MarketBeat
Ginkgo Bioworks to Hold Special Meeting of Shareholders - GuruFocus
Ginkgo Bioworks secures $47M contract from PNNL for phenotyping platform - Investing.com
Ginkgo Bioworks secures $47M contract from PNNL for phenotyping platform By Investing.com - Investing.com South Africa
Ginkgo Bioworks Awarded 4-Year Energy Department Contract Valued at Up to $47 Million - marketscreener.com
Finanzdaten der Ginkgo Bioworks Holdings Inc-Aktie (DNA)
Umsatz
Nettogewinn
Free Cashflow
ENV
28.63%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):